#United States #Sarasota #antibiotic resistance #Lakewood-Amedex #Nu-3

Lakewood-Amedex Biotherapeutics Highlights Resistance Data for Nu-3

In a notable development for the healthcare and biotechnology sectors, Lakewood-Amedex Biotherapeutics Inc. has recently detailed critical resistance data for its candidate, Nu-3. This announcement resonates with the goals of the Presidential Advisory Council on Combating Antibiotic Resistant Bacteria (PACCARB) and reflects a growing commitment to addressing antimicrobial resistance (AMR).

Overview of the PACCARB Meeting

On June 16, 2026, PACCARB convened for its 27th Public Meeting, focusing on the upcoming five-year iteration of the National Action Plan aimed at combating antibiotic-resistant bacteria. This plan is vital as it systematically guides every federal agency’s efforts to tackle AMR, marking a coordinated response to a global health crisis. Kelvin Cooper, Ph.D., CEO of Lakewood-Amedex, emphasized the escalating challenge posed by antimicrobial resistance, characterizing it as one of modern medicine's gravest threats. He stated that urgent action towards developing novel therapeutic platforms like Nu-3 remains a national priority.

Nu-3: A Promising Therapeutic Candidate

Nu-3, a candidate poised for Phase 2 development, targets the treatment of infected diabetic foot ulcers (iDFU). What sets Nu-3 apart is its unique mechanism of action that disrupts bacterial membranes physically, which may not only make it effective but also potentially evade common resistance strategies employed by bacteria. The latest data from Lakewood-Amedex illustrates that Nu-3 maintains a significant barrier to resistance, paving the way for its consideration as a leading candidate in addressing the pressing need for effective treatments.

The company revealed that Nu-3 does not induce resistance, a significant finding confirmed through serial passage experiments. Moreover, laboratory profiles indicated that Nu-3 exhibits broad-spectrum activity against an array of bacteria exhibiting diverse resistance mechanisms. These include infections caused by E. faecalis and E. faecium with vanA and vanB variants, as well as strains resistant to β-lactam antibiotics, proving its versatility and potential in a clinical setting.

Importance of Bypassing Resistance Mechanisms

By successfully bypassing prevalent resistance mechanisms, Lakewood-Amedex's Bisphosphocin® platform reaffirms its commitment to innovating within the sector. The mention of efflux pumps and metabolism resistance from bacteria like E. coli and K. pneumoniae underscores the pressing need for treatments that can circumvent these obstacles. Nu-3's ability to address these issues directly aligns with government initiatives aiming to enhance the pipeline of therapies resilient to antibiotic evasion strategies.

Conclusion

Lakewood-Amedex Biotherapeutics Inc. stands at the forefront of battling AMR with its Bisphosphocin® class. By focusing on developing treatments that not only fight existing infections but also resist the mechanisms that bacteria typically employ to escape therapeutic intervention, the company seeks to provide meaningful solutions for millions suffering from iDFU and beyond. The data shared with PACCARB is a promising indication that the future of antibiotic therapy may pivot significantly with advancements indicated by Nu-3. As the fight against antibiotic resistance gains urgency, Lakewood-Amedex exemplifies the necessary innovation and determination to forge pathways toward effective treatments for critical infections.

For further details about Lakewood-Amedex and its commitment to combating AMR through innovative solutions, interested parties can explore Lakewood-Amedex's official website.